Omeros Q2 Earnings Call Highlights

The brief

Omeros reported second-quarter net sales of $28.5 million for its newly launched treatment YARTEMLEA. The treatment is for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. The company achieved positive operating cash flow and reduced its convertible debt. Omeros is listed on the NASDAQ stock exchange under the ticker symbol OMER. The financial results are significant for the company's growth and financial stability.

Auto-summarised from the full article